Biopharma companies that elect not to provide access to their investigational medicines under the new right-to-try law should publicly post their policies to help protect themselves from “naming and shaming” by unhappy patients, experts say.
Since the right-to-try law has removed FDA as a gatekeeper to preapproval access, companies will now bear all the blame...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?